
ProQR Therapeutics (PRQR) Stock Forecast & Price Target
ProQR Therapeutics (PRQR) Analyst Ratings
Bulls say
ProQR Therapeutics is attractive because its AX-0810 data already show clear dose-dependent target engagement, including up to an 8-fold rise in serum total bile acids, increased circulating TUDCA, and higher plasma conjugated bile acids, while maintaining a favorable safety profile with no SAEs to date. The investment case is strengthened by AX-0811, which management expects to deliver 40%–60% greater editing and longer dosing intervals, with preclinical data suggesting a 1.6-fold longer half-life, >4x greater potency in vivo, and meaningful reductions in hepatocyte, bile duct, and portal vein bile acid burden. Its focus on NTCP modulation is also biologically compelling because human NTCP deficiency appears benign, supporting a differentiated, disease-modifying approach in pediatric biliary atresia and other severe cholestatic diseases.
Bears say
ProQR Therapeutics is weighed down by high clinical and regulatory uncertainty, including safety concerns tied to serial RNA exposure, the risk that Phase Ib/II/III data disappoint, and the possibility that the EMA or FDA interpret results differently or limit approved indications. Its lead biliary atresia program also faces practical execution hurdles such as a narrow enrichment window, biomarker constraints, and a still-unproven regulatory path for surrogate endpoints, which makes clinical validation difficult. Fundamentally, the company remains in a cash-burning, early-development stage and may need additional debt or equity funding that could be dilutive, while facing intense competition from better-resourced RNA and gene-therapy rivals that could make its therapies non-competitive or obsolete.
This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About ProQR Therapeutics (PRQR) Forecast
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares